Advances in multimodal imaging in ophthalmology

Ringel, Morgan J.; Tang, Eric; Tao, Yuankai K.

doi:10.1177/25158414211002400

Cited by 11 publications

(4 citation statements)

References 264 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…En face SLO OCT imaging can provide information on the morphology of vitreous opacities and highlight structural details such as individual vitreous brils to facilitate comparisons between pre-and post-YLV treatment (Figure 2). Dynamic OCT captures the movement of the patient's vitreous in real time, allowing for the localization of vitreous opacities and their shadows as the patient xates on a target or is asked to perform eye movements [19]. Both the depth (Figure 3) and gain (Figure 4) of the OCT B-scan can be manipulated to reveal vitreous opacities that may have been missed on the standard OCT B-scan.…”

Section: Discussionmentioning

confidence: 99%

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

Jiang

Golding²,

Choudhry³

2023

Int Ophthalmol

View full text Add to dashboard Cite

PurposeTo demonstrate the methodology and e cacy of using scanning laser ophthalmoscopy (SLO) and dynamic optical coherence tomography (OCT) to identify and treat symptomatic vitreous oaters using yttrium-aluminum garnet laser vitreolysis (YLV). MethodsThis is a case series highlighted from a cross-sectional retrospective study conducted at the Vitreous Retina Macula Specialists of Toronto. 40 eyes from 35 patients were treated with YLV between November 2018 -December 2020 for symptomatic oaters and imaged with SLO and dynamic OCT. Patients were re-treated with YLV if they reported ongoing signi cant vision symptoms during follow-up which correlated to visible opacities on exam and or imaging. Three cases will be highlighted to present the practical applications of SLO and dynamic OCT imaging for YLV treatment.Results 40 treated eyes were enrolled in this study, with 26 eyes (65%) requiring at least one repeat YLV treatment following the rst treatment due to ongoing symptomatic oaters.Case 1 demonstrates a dense, solitary vitreous opacity that has been localized with dynamic OCT imaging to track its movements and retinal shadowing with the patient's eye movements. Case 2 shows the utility of adjusting the xation target to monitor the movement of vitreous opacities in real-time. Case 3 exhibits an association between decreased symptom burden and vitreous opacity density after YLV. ConclusionImage-guided YLV facilitates the localization and con rmation of vitreous opacities. SLO and dynamic OCT of the vitreous can provide a real-time evaluation of oater size, movement, and morphology, to help clinicians target treatment and monitoring of symptomatic oaters.

show abstract

Section: Discussionmentioning

confidence: 99%

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

Jiang

Golding²,

Choudhry³

2023

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…These eye characteristics lower the risk of systemic exposure. Moreover, advanced non-invasive methods of imaging in the eye, including optical coherence tomography, fundoscopy, angiography, and two-photon microscopy, assist in the real-time monitoring of the progress of the gene therapy procedures and their safety [33]. Another advantageous feature of the eye for gene therapy is that changes in a single gene may be associated with various clinical states.…”

Section: Gene Therapy For Wet Age-related Macular Degenerationmentioning

confidence: 99%

A New Generation of Gene Therapies as the Future of Wet AMD Treatment

Blasiak,

Pawlowska,

Ciupińska

et al. 2024

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is an eye disease and the most common cause of vision loss in the Western World. In its advanced stage, AMD occurs in two clinically distinguished forms, dry and wet, but only wet AMD is treatable. However, the treatment based on repeated injections with vascular endothelial growth factor A (VEGFA) antagonists may at best stop the disease progression and prevent or delay vision loss but without an improvement of visual dysfunction. Moreover, it is a serious mental and financial burden for patients and may be linked with some complications. The recent first success of intravitreal gene therapy with ADVM-022, which transformed retinal cells to continuous production of aflibercept, a VEGF antagonist, after a single injection, has opened a revolutionary perspective in wet AMD treatment. Promising results obtained so far in other ongoing clinical trials support this perspective. In this narrative/hypothesis review, we present basic information on wet AMD pathogenesis and treatment, the concept of gene therapy in retinal diseases, update evidence on completed and ongoing clinical trials with gene therapy for wet AMD, and perspectives on the progress to the clinic of “one and done” therapy for wet AMD to replace a lifetime of injections. Gene editing targeting the VEGFA gene is also presented as another gene therapy strategy to improve wet AMD management.

show abstract

“…These eye characteristics lower the risk of systemic exposure. Moreover, advanced non-invasive methods of imaging in the eye, including optical coherence tomography, fundoscopy, angiography, and two-photon microscopy assist a real-time monitoring of the progress of the gene therapy procedures and their safety [33]. Another advantageous feature of the aye for gene therapy is that changes in a single gene may be associated with various clinical states.…”

Section: Gene Therapy For Wet Age-related Macular Degenerationmentioning

confidence: 99%

New Generation of Gene Therapies as the Future of Wet AMD Treatment

Blasiak,

Pawlowska,

Ciupinska

et al. 2024

Preprint

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is an eye disease and the most common cause of vision loss in the Western World. In its advanced stage, AMD occurs in two clinically distinguished forms: dry and wet, but only wet AMD is treatable. However, the treatment based on repeated injections with vascular endothelial growth factor A (VEGFA) antagonists may at best stop the disease progression and prevent or delay vision loss but without an improvement of visual dysfunction. Moreover, it is a serious mental and financial burden for patients and may be linked with some complications. The recent first success of intravitreal gene therapy with ADVM-022, which transformed retinal cells to continuous production of aflibercept, a VEGF antagonist, after a single injection, has opened a revolutionary perspective in wet AMD treatment. Promising results obtained so far in other ongoing clinical trials support this perspective. In this narrative/hypothesis review, we present basic information on wet AMD pathogenesis and treatment, the idea of gene therapy in retinal diseases, update evidence on completed and ongoing clinical trials with gene therapy for wet AMD, and perspectives on the road to the clinic of “one and done” therapy for wet AMD to replace a lifetime of injections. Gene editing targeting the VEGFA gene is also presented as another gene therapy strategy to improve wet AMD management.

show abstract

Advances in multimodal imaging in ophthalmology

Cited by 11 publications

References 264 publications

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

A New Generation of Gene Therapies as the Future of Wet AMD Treatment

New Generation of Gene Therapies as the Future of Wet AMD Treatment

Contact Info

Product

Resources

About